NasdaqGS:MRNABiotechs
Moderna (MRNA) Is Up 10.1% After Unanimous FDA Panel Backing For mRNA Flu Shot mFlusiva
An FDA advisory committee previously voted unanimously to recommend approval of Moderna’s mRNA-based influenza vaccine, mFlusiva, for adults aged 50 and over, after late-stage trials showed it was around 27% more effective than a standard flu shot.
If the FDA and other health authorities follow this advice, mFlusiva could become the first mRNA flu vaccine and strengthen Moderna’s position in respiratory vaccines for older adults, who represent most flu-related hospitalizations.
We’ll now...

